- Home
- NRT vs INKT Comparison
NRT vs INKT Comparison
Compare NRT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRT
- INKT
- Stock Information
- Founded
- NRT 1975
- INKT 2017
- Country
- NRT United States
- INKT United States
- Employees
- NRT N/A
- INKT N/A
- Industry
- NRT Oil & Gas Production
- INKT Medicinal Chemicals and Botanical Products
- Sector
- NRT Energy
- INKT Health Care
- Exchange
- NRT Nasdaq
- INKT Nasdaq
- Market Cap
- NRT 46.4M
- INKT 48.7M
- IPO Year
- NRT N/A
- INKT 2021
- Fundamental
- Price
- NRT $5.00
- INKT $14.70
- Analyst Decision
- NRT
- INKT Buy
- Analyst Count
- NRT 0
- INKT 3
- Target Price
- NRT N/A
- INKT $37.50
- AVG Volume (30 Days)
- NRT 41.1K
- INKT 174.5K
- Earning Date
- NRT 08-29-2025
- INKT 08-14-2025
- Dividend Yield
- NRT 9.66%
- INKT N/A
- EPS Growth
- NRT 24.05
- INKT N/A
- EPS
- NRT 0.59
- INKT N/A
- Revenue
- NRT $6,184,173.00
- INKT N/A
- Revenue This Year
- NRT N/A
- INKT N/A
- Revenue Next Year
- NRT N/A
- INKT N/A
- P/E Ratio
- NRT $8.63
- INKT N/A
- Revenue Growth
- NRT 18.55
- INKT N/A
- 52 Week Low
- NRT $3.88
- INKT $4.56
- 52 Week High
- NRT $5.92
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- NRT 44.33
- INKT 48.69
- Support Level
- NRT $5.36
- INKT $13.90
- Resistance Level
- NRT $5.75
- INKT $18.17
- Average True Range (ATR)
- NRT 0.21
- INKT 1.95
- MACD
- NRT -0.03
- INKT -0.17
- Stochastic Oscillator
- NRT 30.30
- INKT 47.19
About NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.